{"title":"Bevacizumab May Overcome Clinical Tumor Drug Resistance to IrinotecanBased Chemotherapy in Patients with Metastatic Colorectal Cancer:Case Report","authors":"J. Zekri, M. Abubacker","doi":"10.2174/1876820201003010023","DOIUrl":null,"url":null,"abstract":"Introduction: In the management of patients with metastatic colorectal cancer (mCRC) failing anti-cancer agents/regimens are substituted by others. There is no data in the literature showing that combining 2 failing agents/regimens can induce tumor response. Case: We report a case with mCRC who failed first line XELOX/bevacicumab and second line FOLFIRI. However, the tumour responded to third line FOLFIRI/bevacizumab. Conclusion: Retreatment with bevacizumab in combination with a failing chemotherapy regimen is a possible treatment option after exhaustion of all standard treatments. This approach seems to be effective in overcoming clinical tumor drug resistance to irinotecan based chemotherapy","PeriodicalId":331708,"journal":{"name":"The Open Colorectal Cancer Journal","volume":"54 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2010-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Open Colorectal Cancer Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1876820201003010023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: In the management of patients with metastatic colorectal cancer (mCRC) failing anti-cancer agents/regimens are substituted by others. There is no data in the literature showing that combining 2 failing agents/regimens can induce tumor response. Case: We report a case with mCRC who failed first line XELOX/bevacicumab and second line FOLFIRI. However, the tumour responded to third line FOLFIRI/bevacizumab. Conclusion: Retreatment with bevacizumab in combination with a failing chemotherapy regimen is a possible treatment option after exhaustion of all standard treatments. This approach seems to be effective in overcoming clinical tumor drug resistance to irinotecan based chemotherapy
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
